Sugi Predict

Sugi Predict / Compounds / SCHEMBL2153548

SCHEMBL2153548

SCHEMBL2153548

CC(C)(C)c1cc([N+](=O)[O-])ccc1OC(=O)Oc1ccc([N+](=O)[O-])cc1C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 5/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ GALR3 O60755 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ NR1H4 Q96RI1 3/20 0.48
▸ TDP1 Q9NUW8 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.42
▸ PKM P14618 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ EPHX1 P07099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22428617 0.93 MEN1 (0.47) HTTMEN1KMT2ASMN1; SMN2GALR3
SCHEMBL2153552 0.89 MEN1 (0.50) HTTMEN1KMT2ASMN1; SMN2GALR3
SCHEMBL25874910 0.89 RECQL (0.52) HTTMEN1KMT2ASMN1; SMN2GALR3
SCHEMBL2153555 0.89 MEN1 (0.50) HTTMEN1KMT2ASMN1; SMN2GALR3
SCHEMBL24775 0.88 MEN1 (0.42) HTTMEN1KMT2ASMN1; SMN2GALR3
SCHEMBL17627860 0.84 RECQL (0.43) HTTMEN1KMT2ASMN1; SMN2GALR3
SCHEMBL1530376 0.82 TDP1 (0.60) HTTMEN1KMT2ASMN1; SMN2GALR3
SCHEMBL29223886 0.82 ALDH1A1 (0.43) HTTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6002066 0.81 NR1H4 (0.42) HTTMEN1KMT2ASMN1; SMN2GALR3
SCHEMBL17366570 0.81 HTT (0.48) HTTMEN1KMT2ASMN1; SMN2GALR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250355350-A1 NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED COATING, INTERLAYER INSULATING FILM, SURFACE PROTECTING FILM, AND ELECTRONIC COMPONENT SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-11-20 — — US disclosed
EP-4650874-A1 NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED COATING, INTERLAYER INSULATING FILM, SURFACE PROTECTING FILM, AND ELECTRONIC COMPONENT SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-11-19 — — EP disclosed
US-20120115136-A1 PNA DIAGNOSTIC USE PNA Patent Owners (a/k/a CIG) (US) 2012-05-10 — — US disclosed
EP-1074559-B1 Peptide nucleic acids BUCHARDT OLE (DK) 2011-07-06 — — EP disclosed
US-7378485-B2 Peptide nucleic acids with polyamide-containing backbones BUCHARDT OLE 2008-05-27 — — US disclosed
EP-0773950-B1 LINKED PEPTIDE NUCLEIC ACIDS ISIS PHARMACEUTICALS INC (US) 2007-08-22 — — EP disclosed
US-7223833-B1 Peptide nucleic acid conjugates ISIS PHARMACEUTICALS, INC. (US) 2007-05-29 — — US disclosed
US-20060160731-A1 Peptide nucleic acids BUCHARDT OLE 2006-07-20 — — US disclosed
EP-1411063-B1 Peptide nucleic acids BUCHARDT OLE (DK) 2006-07-19 — — EP disclosed
US-20060046255-A1 Use of nucleic acid analogues in diagnostics and analytical procedures BUCHARDT OLE 2006-03-02 — — US disclosed
EP-0773950-A1 LINKED PEPTIDE NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 1997-05-21 — — EP disclosed
US-5539082-A Peptide nucleic acids NIELSEN PETER E (DK) 1996-07-23 — — US disclosed
WO-1996011205-A9 PEPTIDE NUCLEIC ACID CONJUGATES — 1996-05-30 — — WO disclosed
WO-1996011205-A1 PEPTIDE NUCLEIC ACID CONJUGATES ISIS PHARMACEUTICALS, INC. (US) 1996-04-18 — — WO disclosed
WO-1996002558-A1 LINKED PEPTIDE NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 1996-02-01 — — WO disclosed
WO-1995001370-A1 HIGHER ORDER STRUCTURE AND BINDING OF PEPTIDE NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 1995-01-12 — — WO disclosed
EP-0586618-A1 THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES. BUCHARDT OLE (DK) 1994-03-16 — — EP disclosed
EP-0586474-A1 PEPTIDE NUCLEIC ACIDS BUCHARDT, Ole (DK) 1994-03-16 — — EP disclosed
WO-1992020702-A1 PEPTIDE NUCLEIC ACIDS BUCHARDT OLE (DK) 1992-11-26 — — WO disclosed
WO-1992020703-A1 THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES BUCHARDT OLE (DK) 1992-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115136-A1 PNA DIAGNOSTIC USE RNASE1, NCL, PABPC4 HTT 2104/4885MEN1 1735/4885KMT2A 3327/4885
US-20060046255-A1 Use of nucleic acid analogues in diagnostics and analytical procedures ADAR, POLRMT, POLI HTT 722/4885MEN1 1103/4885KMT2A 3419/4885
US-20060160731-A1 Peptide nucleic acids RNGTT, POLM, POLRMT HTT 719/4885MEN1 1408/4885KMT2A 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.